sip valuation???, page-6

Remember ... Current sp is a reflection of the company's future value as seen by the market. Hence, $900m sale = no debt, but what is going to be left? A company that 1. keeps dropping its forecast earnings, 2. has lost Pfizer, 3. is getting squeezed by changes in govt policy, 4. having trouble with pharmacies paying accounts, and 5. has lost a huge chunk of its assets to Aspen. The immediate future doesn't look bright at all. Personally, I am voting against the sale to Aspen, for all the good that will do. I still think that the Pharmaceutical Division is the best part of this company.